Kairos Pharma, Ltd. (KAPA)

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on cancer therapies, particularly on overcoming the drug resistance and immune suppression that limit the effectiveness of existing treatments. Its lead candidate, ENV105, is an antibody that targets CD105, a protein that tumors can upregulate as a way of escaping the effect of standard therapies.

The company is evaluating ENV105 in combination with established drugs in cancers such as prostate cancer and non-small cell lung cancer, with the goal of restoring or prolonging patients' response to treatment. It also has earlier-stage research programs in immuno-oncology.

Kairos Pharma is based in Los Angeles, California, and its common stock began trading on the NYSE American in 2024.